Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2024; 30(23): 2964-2980
Published online Jun 21, 2024. doi: 10.3748/wjg.v30.i23.2964
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
Jakub Rochoń, Piotr Kalinowski, Ksenia Szymanek-Majchrzak, Michał Grąt
Jakub Rochoń, Piotr Kalinowski, Michał Grąt, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw 02-097, Poland
Ksenia Szymanek-Majchrzak, Department of Medical Microbiology, Medical University of Warsaw, Warsaw 02-004, Poland
Author contributions: Rochoń J and Kalinowski P reviewed the literature and drafted the original manuscript; Rochoń J and Szymanek-Majchrzak K designed the figures; Rochoń J, Kalinowski P, Szymanek-Majchrzak K and Grąt M critically revised the manuscript for important intellectual content. All of the authors contributed to the study conception and design. All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Piotr Kalinowski, MD, PhD, Associate Professor, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Banacha 1a st., Warsaw 02-097, Poland. piotr.kalinowski@wum.edu.pl
Received: February 29, 2024
Revised: May 8, 2024
Accepted: May 24, 2024
Published online: June 21, 2024
Processing time: 112 Days and 8 Hours
Core Tip

Core Tip: Dysbiosis of gut microbiota leading to gut-liver axis disruption is a significant contributor to the development of metabolic dysfunction-associated fatty liver disease (MAFLD). However, the precise role of enteric bacteria in the pathogenesis of MAFLD remains unclear. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may modulate MAFLD progression mechanisms to alleviate dysfunction, partly by modifying gut microbiota. The association between MAFLD pathogenesis and gut microbiota dysbiosis needs to be understood, as well as how GLP-1 RAs can regulate these impaired mechanisms and improve patient outcomes.